In the Journals

Ceramide-infused skin barrier reduces costs, complications in ostomy care

Using an ostomy skin barrier infused with ceramide resulted in lower costs and improved satisfaction for patients, according to a study published in the Journal of Wound, Continence and Ostomy Nursing.

Janice C. Colwell, MS, RN, CWOCN, FAAN, of University of Chicago Medicine, and colleagues conducted what they called the ADVOCATE study to determine the outcomes in both skin condition and economic impact of the CeraPlus skin barrier (Hollister Incorporated).

“We know that peristomal skin complications affect the majority of people living with stoma and present a significant burden in terms of quality of life, as well as higher overall health care costs for the health care system and the patients it serves,” Colwell said in a press release.

The investigators stratified 153 patients from 25 sites in the United States, Canada and Europe into either a treatment group or a control group.

During the 12-week trial, researchers tested the patients peristomal skin conditions (PSCs), like skin inflammation or damage, and analyzed the cost of patient care.

They found that the use of the ceramide-infused skin barrier significantly reduced stoma-related cost of care during the 12-week period. The adjusted average costs were $223.73 for the treatment group and $260.19 in the control group (P = .017). The overall incidence of PSCs was 47.7%. Patients in the treatment group experienced fewer PSCs (40.5%) compared with patients in the control group (55.4%).

“The results of the ADVOCATE study show that a skin barrier infused with ceramide can have a positive impact on both patient outcomes and economic burden, by reducing the incidence of peristomal complications and significantly reducing the stoma-related cost of care,” Colwell said in the press release.by Alex Young

Disclosures: The study was funded by Hollister Incorporated. Colwell reports being a speaker for Hollister and Coloplast and consulting for Coloplast. Please see the full study for the other authors’ relevant disclosures.

Using an ostomy skin barrier infused with ceramide resulted in lower costs and improved satisfaction for patients, according to a study published in the Journal of Wound, Continence and Ostomy Nursing.

Janice C. Colwell, MS, RN, CWOCN, FAAN, of University of Chicago Medicine, and colleagues conducted what they called the ADVOCATE study to determine the outcomes in both skin condition and economic impact of the CeraPlus skin barrier (Hollister Incorporated).

“We know that peristomal skin complications affect the majority of people living with stoma and present a significant burden in terms of quality of life, as well as higher overall health care costs for the health care system and the patients it serves,” Colwell said in a press release.

The investigators stratified 153 patients from 25 sites in the United States, Canada and Europe into either a treatment group or a control group.

During the 12-week trial, researchers tested the patients peristomal skin conditions (PSCs), like skin inflammation or damage, and analyzed the cost of patient care.

They found that the use of the ceramide-infused skin barrier significantly reduced stoma-related cost of care during the 12-week period. The adjusted average costs were $223.73 for the treatment group and $260.19 in the control group (P = .017). The overall incidence of PSCs was 47.7%. Patients in the treatment group experienced fewer PSCs (40.5%) compared with patients in the control group (55.4%).

“The results of the ADVOCATE study show that a skin barrier infused with ceramide can have a positive impact on both patient outcomes and economic burden, by reducing the incidence of peristomal complications and significantly reducing the stoma-related cost of care,” Colwell said in the press release.by Alex Young

Disclosures: The study was funded by Hollister Incorporated. Colwell reports being a speaker for Hollister and Coloplast and consulting for Coloplast. Please see the full study for the other authors’ relevant disclosures.